CO5611109A2 - Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2 - Google Patents

Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2

Info

Publication number
CO5611109A2
CO5611109A2 CO04079024A CO04079024A CO5611109A2 CO 5611109 A2 CO5611109 A2 CO 5611109A2 CO 04079024 A CO04079024 A CO 04079024A CO 04079024 A CO04079024 A CO 04079024A CO 5611109 A2 CO5611109 A2 CO 5611109A2
Authority
CO
Colombia
Prior art keywords
delta
cyclooxygenasa
alfa
binding
combinations
Prior art date
Application number
CO04079024A
Other languages
English (en)
Spanish (es)
Inventor
Taylor Charles Price Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5611109A2 publication Critical patent/CO5611109A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO04079024A 2002-02-22 2004-08-13 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2 CO5611109A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
CO5611109A2 true CO5611109A2 (es) 2006-02-28

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04079024A CO5611109A2 (es) 2002-02-22 2004-08-13 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (enExample)
EP (1) EP1480639A1 (enExample)
JP (1) JP2005523281A (enExample)
KR (1) KR20040085216A (enExample)
CN (1) CN1635887A (enExample)
AR (1) AR038531A1 (enExample)
AU (1) AU2003246864A1 (enExample)
BR (1) BR0307906A (enExample)
CA (1) CA2476438A1 (enExample)
CO (1) CO5611109A2 (enExample)
HN (1) HN2003000071A (enExample)
IL (1) IL162932A0 (enExample)
MX (1) MXPA04008175A (enExample)
NO (1) NO20043947L (enExample)
PA (1) PA8567201A1 (enExample)
PE (1) PE20031052A1 (enExample)
PL (1) PL372210A1 (enExample)
RU (1) RU2286151C2 (enExample)
TW (1) TW200303214A (enExample)
UY (1) UY27675A1 (enExample)
WO (1) WO2003070237A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341240T3 (es) * 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
JP2006520799A (ja) * 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ, インコーポレイテッド 平滑筋調節因子およびα2δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
EP2007723A2 (en) * 2006-04-11 2008-12-31 Novartis AG Organic compounds
CN101610761A (zh) * 2006-12-22 2009-12-23 诺瓦提斯公司 作为ddp-iv抑制剂的1-氨基甲基-l-苯基-环己烷衍生物
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
CA3200132A1 (en) * 2020-10-28 2022-05-05 Tremeau Pharmaceuticals, Inc. Aqueous formulations of water insoluble cox-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
HU0102041D0 (en) * 1994-07-27 2001-07-30 Warner Lambert Co Pharmacological compounds which bind to [3h]-gabapentine binding protein
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
IL135315A0 (en) * 1997-12-16 2001-05-20 Warner Lambert Co 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2359485A1 (en) * 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib

Also Published As

Publication number Publication date
AR038531A1 (es) 2005-01-19
UY27675A1 (es) 2003-09-30
MXPA04008175A (es) 2004-11-26
PA8567201A1 (es) 2003-11-12
NO20043947L (no) 2004-09-21
TW200303214A (en) 2003-09-01
CN1635887A (zh) 2005-07-06
EP1480639A1 (en) 2004-12-01
AU2003246864A1 (en) 2003-09-09
WO2003070237A1 (en) 2003-08-28
HN2003000071A (es) 2003-11-24
JP2005523281A (ja) 2005-08-04
PE20031052A1 (es) 2003-12-24
RU2004125609A (ru) 2006-01-27
RU2286151C2 (ru) 2006-10-27
PL372210A1 (en) 2005-07-11
BR0307906A (pt) 2004-12-21
KR20040085216A (ko) 2004-10-07
IL162932A0 (en) 2005-11-20
CA2476438A1 (en) 2003-08-28
US20030199567A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
CO5611109A2 (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2
NO20034644D0 (no) Fettsyrer med halvlange kjeder, glycerider og analoger som neutrofile overlevelses- og aktiveringsfaktorer
CO5611113A2 (es) Tripeptidos que poseen un eter de hidroxiprolina de una quinolina sustituida para la inhibicion de ns3 (hepatitis c)
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
AR039701A1 (es) Combinaciones de compuestos activos fungicidas
AR048282A1 (es) Indol- o - glucosidos sustituidos
CR9614A (es) Inhibidores heterobiciclicos de las metaloproteasas
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
DK2135608T3 (da) S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase
CR6682A (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorios, autoinmunes y respiratorias
AR016523A1 (es) Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
ES2187077T3 (es) Mezclas fungicidas a base de compuestos de amida.
ATE457977T1 (de) Biguanidderivate
PA8542201A1 (es) Inhibidores de pcp basados en acidos-3-heterociclilpropanohidroxamicos
AR028958A1 (es) INHIBIDORES DE TRANSCRIPTASA INVERSA NO NUCLEoSIDOS
GEP20074257B (en) Novel method for the synthesis of s-indoline-2-carboxylic acid and application thereof in the synthesis of perindopril
AR012048A2 (es) Derivados del acido fenil cicloalquilcarboxilicos y el uso de los mismos
AR044175A1 (es) Compuestos de cefemo
CO5700781A2 (es) Agonistas morfolinicos de la dopamina
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
AR042037A1 (es) Profarmaco de celecoxib
CR8340A (es) Pirazolilcarboxanilidas n-sustituidas
BR0312963A (pt) Couro antimicrobiano durável

Legal Events

Date Code Title Description
FC Application refused